NTLA
Intellia Therapeutics, Inc. NASDAQ Listed May 6, 2016$13.71
Mkt Cap $1.6B
52w Low $6.83
32.1% of range
52w High $28.25
50d MA $13.66
200d MA $13.18
P/E (TTM)
-3.5x
EV/EBITDA
-2.3x
P/B
2.1x
Debt/Equity
0.1x
ROE
-61.5%
P/FCF
-2.7x
RSI (14)
—
ATR (14)
—
Beta
1.99
50d MA
$13.66
200d MA
$13.18
Avg Volume
4.3M
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
40 Erie Street · Cambridge, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 13.85 | -0.5% | -1.0% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.99 | -0.83 | +16.2% | 14.28 | -3.1% | -3.5% | +12.0% | -11.9% | +1.5% | -4.8% | — |
| Nov 6, 2025 | AMC | -1.02 | -0.92 | +9.8% | 12.32 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% | — |
| Aug 7, 2025 | AMC | -1.03 | -0.99 | +3.9% | 11.46 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% | — |
| May 8, 2025 | AMC | -1.26 | -1.10 | +12.7% | 8.28 | +1.7% | -1.9% | +5.3% | -2.7% | -5.3% | +2.4% | — |
| Feb 27, 2025 | AMC | -1.32 | -1.24 | +6.1% | 10.86 | -5.4% | -7.1% | -6.3% | -3.7% | +3.0% | +5.7% | — |
| Nov 7, 2024 | AMC | -1.37 | -1.34 | +2.2% | 16.00 | +0.3% | +4.6% | +4.6% | -4.9% | -3.2% | -6.1% | — |
| Aug 8, 2024 | AMC | -1.21 | -1.31 | -8.3% | 22.38 | +0.1% | -4.1% | +1.4% | +2.9% | -4.0% | +6.3% | — |
| May 9, 2024 | AMC | -1.35 | -1.06 | +21.5% | 24.86 | +0.6% | -1.6% | +3.9% | +1.2% | +1.9% | -0.2% | — |
| Feb 22, 2024 | AMC | -1.47 | -1.46 | +0.7% | 27.18 | -1.7% | -4.0% | +6.0% | +12.1% | +5.7% | -2.1% | — |
| Nov 9, 2023 | AMC | -1.52 | -1.38 | +9.2% | 24.96 | +0.4% | -3.3% | -1.3% | +11.1% | +0.5% | -2.1% | — |
| Aug 3, 2023 | AMC | -1.32 | -1.40 | -6.1% | 39.09 | +1.2% | +1.3% | -1.5% | +2.5% | +0.0% | -1.2% | — |
| May 4, 2023 | AMC | -1.41 | -1.17 | +17.0% | 43.65 | +1.2% | +0.6% | -1.6% | +1.8% | +2.8% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Citizens | Maintains | Market Outperform → Market Outperform | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 28 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 28 | Goldman Sachs | Maintains | Sell → Sell | — | $13.04 | $12.82 | -1.7% | +1.2% | -5.7% | +8.3% | -1.6% | +4.6% |
| Apr 27 | Baird | Maintains | Neutral → Neutral | — | $13.63 | $14.23 | +4.4% | -4.3% | +1.2% | -5.7% | +8.3% | -1.6% |
| Apr 27 | Chardan Capital | Maintains | Buy → Buy | — | $13.63 | $14.23 | +4.4% | -4.3% | +1.2% | -5.7% | +8.3% | -1.6% |
| Mar 4 | Jones Trading | Upgrade | Hold → Buy | — | $13.61 | $13.98 | +2.7% | +1.5% | -4.8% | +2.2% | +3.3% | -3.0% |
| Mar 3 | Leerink Partners | Maintains | Outperform → Outperform | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 3 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $15.44 | $14.79 | -4.2% | -11.9% | +1.5% | -4.8% | +2.2% | +3.3% |
| Mar 2 | Chardan Capital | Maintains | Buy → Buy | — | $13.78 | $13.79 | +0.1% | +12.0% | -11.9% | +1.5% | -4.8% | +2.2% |
| Feb 27 | Chardan Capital | Maintains | Buy → Buy | — | $14.28 | $13.84 | -3.1% | -3.5% | +12.0% | -11.9% | +1.5% | -4.8% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.83 | $14.97 | +0.9% | -6.8% | +0.6% | -5.4% | -0.7% | -0.1% |
| Nov 12 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $10.18 | $10.02 | -1.6% | -6.8% | -8.6% | +0.3% | -2.5% | -0.1% |
| Nov 11 | Evercore ISI | Downgrade | Outperform → In Line | — | $9.73 | $9.59 | -1.4% | +4.6% | -6.8% | -8.6% | +0.3% | -2.5% |
| Nov 11 | Jones Trading | Downgrade | Buy → Hold | — | $9.73 | $9.59 | -1.4% | +4.6% | -6.8% | -8.6% | +0.3% | -2.5% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.52 | $10.71 | +12.5% | +2.2% | +4.6% | -6.8% | -8.6% | +0.3% |
| Nov 10 | Truist | Maintains | Buy → Buy | — | $9.52 | $10.71 | +12.5% | +2.2% | +4.6% | -6.8% | -8.6% | +0.3% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Wedbush | Maintains | Neutral → Neutral | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | JP Morgan | Downgrade | Neutral → Underweight | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $12.32 | $9.15 | -25.7% | -22.7% | +2.2% | +4.6% | -6.8% | -8.6% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.12 | $11.78 | -10.2% | -6.5% | +2.9% | +3.6% | -6.7% | +11.2% |
| Oct 28 | Bernstein | Downgrade | Outperform → Market Perform | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | Barclays | Maintains | Overweight → Overweight | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 28 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $14.79 | $14.78 | -0.1% | -5.6% | -6.0% | -6.5% | +2.9% | +3.6% |
| Oct 27 | BofA Securities | Maintains | Buy → Buy | — | $25.60 | $13.73 | -46.4% | -42.2% | -5.6% | -6.0% | -6.5% | +2.9% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.60 | $13.73 | -46.4% | -42.2% | -5.6% | -6.0% | -6.5% | +2.9% |
| Oct 27 | Chardan Capital | Maintains | Buy → Buy | — | $25.60 | $13.73 | -46.4% | -42.2% | -5.6% | -6.0% | -6.5% | +2.9% |
| Oct 6 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $19.96 | $21.06 | +5.5% | +2.9% | -0.5% | +19.7% | +4.0% | -3.7% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.11 | $16.42 | +1.9% | -3.2% | +10.7% | -1.0% | +4.0% | -6.5% |
| Sep 19 | JMP Securities | Maintains | Market Perform → Market Perform | — | $16.11 | $16.42 | +1.9% | -3.2% | +10.7% | -1.0% | +4.0% | -6.5% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $10.86 | $10.99 | +1.2% | +1.3% | -0.9% | +0.8% | -2.4% | -4.1% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $10.79 | $10.92 | +1.2% | -0.5% | +1.1% | +1.3% | -0.9% | +0.8% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.46 | $11.51 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.46 | $11.51 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $11.46 | $11.51 | +0.4% | -5.8% | -0.5% | +1.1% | +1.3% | -0.9% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.31 | $8.54 | +2.8% | +7.8% | +6.9% | +0.2% | -4.2% | +0.3% |
| Jun 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.16 | $7.27 | +1.5% | +7.4% | -0.3% | -1.2% | +6.7% | +2.3% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.66 | $7.37 | -23.7% | -22.9% | -7.8% | +4.2% | +7.4% | -0.3% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.06 | $9.04 | -0.2% | +6.7% | -4.9% | +2.8% | -3.2% | +1.7% |
| May 19 | Wedbush | Maintains | Neutral → Neutral | — | $8.50 | $8.55 | +0.6% | +6.6% | +6.7% | -4.9% | +2.8% | -3.2% |
No insider trades available.
8-K
Intellia Therapeutics, Inc. -- 8-K Filing
Intellia Therapeutics completed an underwritten public offering under its shelf registration, with standard indemnification provisions protecting underwriters from securities law liabilities.
Apr 30
8-K · 7.01
! Medium
Intellia Therapeutics, Inc -- 8-K 7.01: Regulation FD Disclosure
Intellia Therapeutics disclosed material information via press release and presentation, requiring investors to review the furnished exhibits for details on company developments or announcements.
Apr 27
8-K
Unknown — 8-K Filing
Intellia Therapeutics updated its corporate bylaws, likely reflecting governance changes that could affect shareholder voting rights, board structure, or operational procedures—investors should review specifics for potential impacts on corporate control.
Apr 10
8-K · 7.01
! Medium
Intellia Therapeutics, Inc -- 8-K 7.01: Regulation FD Disclosure
Intellia Therapeutics (NTLA) can resume its MAGNITUDE Phase 3 clinical trial for ATTR-CM treatment after the FDA lifted a clinical hold, potentially accelerating the company's path toward commercialization.
Mar 2
8-K
Intellia Therapeutics, Inc -- 8-K Filing
Intellia Therapeutics expects to submit a lonvo-z BLA for hereditary angioedema in late 2026 with anticipated U.S. launch in early 2027, while reactivating its MAGNITUDE-2 trial for nex-z in ATTR amyloidosis.
Feb 26
Data updated apr 26, 2026 3:59pm
· Source: massive.com